HEMISPHERX BIOPHARMA INC (HEB) Stock Price & Overview
NYSEARCA:HEB
Current stock price
The current stock price of HEB is 1.8 null. Today HEB is down by -0.55%. In the past month the price decreased by -19.28%. In the past year, price decreased by -85.12%.
HEB Key Statistics
- Market Cap
- 4.396M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.54
- Dividend Yield
- N/A
HEB Stock Performance
HEB Stock Chart
HEB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HEB. When comparing the yearly performance of all stocks, HEB is a bad performer in the overall market: 99.22% of all stocks are doing better.
HEB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HEB. HEB has a bad profitability rating. Also its financial health evaluation is rather negative.
HEB Earnings
HEB Forecast & Estimates
HEB Financial Highlights
Over the last trailing twelve months HEB reported a non-GAAP Earnings per Share(EPS) of -5.540000000000001. The EPS decreased by -2418.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -3284.04% | ||
| ROA | -73.02% | ||
| ROE | -153.97% | ||
| Debt/Equity | 0.37 |
HEB Ownership
About HEB
Company Profile
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.
Company Info
HEMISPHERX BIOPHARMA INC
2117 SW HIGHWAY 484
OCALA FL 34473
CEO: Thomas K. Equels
Phone: 215-988-0080
HEMISPHERX BIOPHARMA INC / HEB FAQ
What does HEB do?
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.
Can you provide the latest stock price for HEMISPHERX BIOPHARMA INC?
The current stock price of HEB is 1.8 null. The price decreased by -0.55% in the last trading session.
Does HEB stock pay dividends?
HEB does not pay a dividend.
How is the ChartMill rating for HEMISPHERX BIOPHARMA INC?
HEB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is HEMISPHERX BIOPHARMA INC worth?
HEMISPHERX BIOPHARMA INC (HEB) has a market capitalization of 4.40M null. This makes HEB a Nano Cap stock.